Optimize Your High-Value Cell Lines: Accelerate Cell Line Development For Recombinant Proteins And Monoclonal Antibody Production

This content is brought to you by Molecular Devices, a Danaher Operating Company.

The production of monoclonal antibodies (mAbs) and recombinant proteins using mammalian cells has significantly transformed the biotherapeutics market. In 2022, recombinant cell lines dominated the market, holding the highest share at 31.79%. The global cell line development market, currently valued at over $5 billion USD, is projected to grow at a compound annual growth rate (CAGR) of 9.81%. By 2030, it is expected to reach a revenue forecast exceeding $10 billion USD. This robust growth is primarily driven by the increasing demand for biologics, particularly monoclonal antibodies.

Examine a comprehensive overview of the cell line development workflow and high-throughput solutions designed to accelerate the process that makes the selection of high-producing mammalian cell lines easier and faster.